Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Cited by 155 Publications

Cell, 2019, 176(5):1083-1097

PubMed: 30739799 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290.CD-18-0830

PubMed: 31594766 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Cancer Discov, 2017, 7(10):1168-1183

PubMed: 28801307 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(4):489-501

PubMed: 28965767 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 27(1):92-104

PubMed: 31925410 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Gut, 2019, 68(2):207-217

PubMed: 29703791 ( click the link to review the publication )

Nat Microbiol, 2019, 4(12):2260-2272

PubMed: 31548682 ( click the link to review the publication )

Mol Cell, 2019, 76(4):562-573

PubMed: 31543423 ( click the link to review the publication )

Mol Cell, 2019, 73(1):22-35.e6

PubMed: 30527665 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1373

PubMed: 30914635 ( click the link to review the publication )

Nat Commun, 2019, 10(1):557

PubMed: 30718506 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(8):3921-3936

PubMed: 30805632 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2769

PubMed: 30692100 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2466-2479

PubMed: 30940663 ( click the link to review the publication )
Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2667-2680

PubMed: 30840889 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.119.232603

PubMed: 31481582 ( click the link to review the publication )

Oncogene, 2019, 38(20):3886-3902

PubMed: 30692638 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31100952 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):271

PubMed: 30894510 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):376

PubMed: 31092814 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(10)

PubMed: 31590445 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(2):300-306

PubMed: 30595531 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):771-779

PubMed: 30837298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0162

PubMed: 31395685 ( click the link to review the publication )

Mol Oncol, 2019, 13(8):1778-1794

PubMed: 31180176 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(1):465-489

PubMed: 29721855 ( click the link to review the publication )

Eur J Med Chem, 2019, 165:115-132

PubMed: 30665142 ( click the link to review the publication )

Oncogenesis, 2019, 8(7):38

PubMed: 31209198 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 163:133-141

PubMed: 30772267 ( click the link to review the publication )

J Transl Med, 2019, 17(1):245

PubMed: 31358010 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13405

PubMed: 31527634 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )
Sci Rep, 2019, 9(1):13696

PubMed: 31548560 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29249

PubMed: 31264276 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1685289

PubMed: 31747859 ( click the link to review the publication )

Exp Cell Res, 2019, 10.1016/j.yexcr.2019.111782

PubMed: 31857114 ( click the link to review the publication )

Am J Transl Res, 2019, 11(6):3481-3489

PubMed: 31312360 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(4):967-973

PubMed: 31005255 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Oncol Lett, 2019, 17(1):1153-1159

PubMed: 30655877 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:22

PubMed: 31372497 ( click the link to review the publication )

NPJ Precis Oncol, 2019, 03:18

PubMed: 31341951 ( click the link to review the publication )

Haematologica, 2019, 104(2):347-359

PubMed: 30262555 ( click the link to review the publication )

Oncotarget, 2019, 10(47):4907-4918

PubMed: 31448056 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Gut, 2018, 10.1136/gutjnl-2017-314544

PubMed: 29884612 ( click the link to review the publication )

Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(12):6188-6205

PubMed: 29873780 ( click the link to review the publication )

Autophagy, 2018, 14(4):637-653

PubMed: 29368982 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3994-4005

PubMed: 29716919 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-3094

PubMed: 30538112 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4360-4369

PubMed: 29844123 ( click the link to review the publication )
Cell Rep, 2018, 24(5):1105-1112.e5

PubMed: 30067968 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(37):5066-5078

PubMed: 29789718 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):446

PubMed: 29670090 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):897-907

PubMed: 29483214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582

PubMed: 29452249 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cell Signal, 2018, 44:1-9

PubMed: 29284139 ( click the link to review the publication )

J Orthop Res, 2018, 36(6):1581-1589

PubMed: 29194728 ( click the link to review the publication )

Cell Cycle, 2018, 17(11):1329-1344

PubMed: 30037299 ( click the link to review the publication )

Cell Cycle, 2018, 17(14):1784-1796

PubMed: 29995568 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):424-430

PubMed: 29477843 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 102(5):1569-1576

PubMed: 30056081 ( click the link to review the publication )

Oncotarget, 2018, 9(77):34567-34581

PubMed: 30349650 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2018, 21(5):375-382

PubMed: 29764587 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1061-1070

PubMed: 28759028 ( click the link to review the publication )

Mol Cell, 2017, 68(6):1134-1146

PubMed: 29225033 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )
Nat Commun, 2017, 8(1):1193

PubMed: 29084956 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )

Nat Commun, 2017, 8(1):241

PubMed: 28808226 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1415-1433

PubMed: 28778953 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

Dev Cell, 2017, 43(4):449-462

PubMed: 29103955 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.26957

PubMed: 29889021 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):123

PubMed: 28629371 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(15):2427-2443

PubMed: 28444744 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1942-1953

PubMed: 28566433 ( click the link to review the publication )

Cell Oncol (Dordr), 2017, 40(3):209-218

PubMed: 28243976 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(3):676-688

PubMed: 27338091 ( click the link to review the publication )

Protein Sci, 2017, 26(4):870-879

PubMed: 28168755 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(56):95116-95134

PubMed: 29221116 ( click the link to review the publication )

Oncotarget, 2017, 8(34):55848-55862

PubMed: 28915557 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47239-47249

PubMed: 28525384 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:11581

PubMed: 27181366 ( click the link to review the publication )

Nat Commun, 2016, 7:12748

PubMed: 27599659 ( click the link to review the publication )

Nat Commun, 2016, 7:11302

PubMed: 27066737 ( click the link to review the publication )

Nat Commun, 2016, 7:11987

PubMed: 27329820 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(1):122-33

PubMed: 26728409 ( click the link to review the publication )
Cell Mol Life Sci, 2016, 73(4):883-900

PubMed: 26346493 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2486-2497

PubMed: 27507850 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

J Cancer, 2016, 7(8):947-56

PubMed: 27313785 ( click the link to review the publication )

J Immunol, 2016, 197(7):2673-85

PubMed: 27566829 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(26):39595-39608

PubMed: 27167191 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51163-51173

PubMed: 27323399 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69111-69123

PubMed: 27564114 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

J Exp Med, 2015, 212(6):953-70

PubMed: 26008897 ( click the link to review the publication )

J Cell Biol, 2015, 210(7):1257-68

PubMed: 26416968 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:76

PubMed: 26225123 ( click the link to review the publication )

Anticancer Res, 2015, 35(12):6623-32

PubMed: 26637878 ( click the link to review the publication )

Data Brief, 2015, 5:429-33

PubMed: 26958605 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):662-74

PubMed: 24362465 ( click the link to review the publication )

AIDS, 2014, 28(15):2213-22

PubMed: 25036183 ( click the link to review the publication )

FEBS J, 2014, 281(18):4179-94

PubMed: 24823279 ( click the link to review the publication )

BMC Cancer, 2014, 14:32

PubMed: 24444383 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )

Cell Death Differ, 2013, 20(9):1241-9

PubMed: 23852369 ( click the link to review the publication )
Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

Pharmacogenomics J, 2013, 13(1):94-104

PubMed: 22083351 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cell Cycle, 2013, 12(15):2384-94

PubMed: 23839043 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4612-20

PubMed: 22761470 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2012, 26(2):236-46

PubMed: 23279822 ( click the link to review the publication )

Am J Cancer Res, 2012, 2(6):726-35

PubMed: 23226618 ( click the link to review the publication )

Cell Cycle, 2012, 11(19):3599-610

PubMed: 22935696 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51847

PubMed: 23300567 ( click the link to review the publication )

georgetown university, 2012, georgetown university

PubMed: ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Features

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Targets

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	MV\LbY5ie2ViQYPzZZk>		NHSxcm0zPCCq		MnfyTY5pcWKrdHnvckBw\iCFRFu0JIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gVoIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwNkDPxE1?	M2GzfVI1PjRzMUCz
COLO205	Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXPqU\|k4PzJiaB?=		Mn[1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB\|NjFOwG0>	M2\hOVI1PjRzMUCz
U937	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFzo[FA4OiCq		MoHJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=>	MWOyOFY1OTFyMx?=
MOLM13	NULZS\|c4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVm3NkBp		MkLoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zNNVMh[2WubIOgbIFz[m:{aX7nJGZNXDNiSWTEJI12fGGwdDDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODl4IN88US=>	M1nCRVI1PjRzMUCz
MOLM13	MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXqyV2ZuPzJiaB?=		MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO	M4D0[FI1PjRzMUCz
MDA-MB-435	MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXPiUXNFOjRiaB?=		M3PiXWlEPTB;MD6xOkDPxE1?	MVWxOVgxOTh\|MR?=
K562	MVrDfZRwfG:6aXOgRZN{[Xl?		NIfn[Ic6PiCq	NUHpSGhGTE2VTx?=	MX3JR\|UxRTJizszN	M1OzSFI1PDF5NU[2
DU145	NFHQUJlEgXSxdH;4bYMhSXO\|YYm=		NV;ac\|VvQTZiaB?=	M1XMR2ROW09?	NV7zc49DUUN3ME23MlUh\|ryP	NHzWfYEzPDRzN{W2Oi=>
MDA-MB-231	M17xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXKyWXljOSEQvF2=	NYXL[mFPOjRiaB?=	M3\nOWROW09?	MkiwR4VtdCCleXPs[UBienKnc4SgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl	MX2yOFQyPzV4Nh?=
MCF7	NYrsdWdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLKNUDPxE1?	NY\nZYpVOjRiaB?=	NIH5V21FVVOR	NYjxWJdMS2WubDDjfYNt\SCjcoLld5Qh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm	NUXJW5ZJOjR2MUe1OlY>
MCF7	NYTPXpY2U2mwYYPlJGF{e2G7	NHv3OFc2KM7:TR?=	M{j5OFI1KGh?	MVjEUXNQ	MoDRTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?=	MmXXNlQ1OTd3Nk[=
MDA-MB-231	MWfLbY5ie2ViQYPzZZk>	MXu1JO69VQ>?	NGTKPZIzPCCq	NEW5TnRFVVOR	NX6zO4pkUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=>	NFLXVIszPDRzN{W2Oi=>
MDA-MB-231	NGTlb3BHfW6ldHnvckBCe3OjeR?=	NWP5NllOOS1zMDFOwG0>	MnLXNlQhcA>?	M{jO[WROW09?	NIHxZVJld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W\|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W=	NH\UcoMzPDRzN{W2Oi=>
MCF7	Mk\KSpVv[3Srb36gRZN{[Xl?	M3fyNlEuOTBizszN	M2j2PFI1KGh?	MWrEUXNQ	NXvVVHhV\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl	MXSyOFQyPzV4Nh?=
MDA-MB-231	M4O3cGZ2dmO2aX;uJGF{e2G7	MWewMlUuOSEQvF2=	MlK4OFghcA>?	NGHWbpdFVVOR	MnLQbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U>	NIniXHAzPDRzN{W2Oi=>
MCF7	MYTGeY5kfGmxbjDBd5NigQ>?	MXWwMlUuOSEQvF2=	NIPDUI81QCCq	NI[wXHFFVVOR	M1LLNYhieyCwbzDD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm	MXqyOFQyPzV4Nh?=
697	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrJXVRJUUN3ME2xOFgvOzhibl2=	M3j0T3NCVkeHUh?=
P12-ICHIKAWA	MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTl4LkC0JI5O	MUPTRW5ITVJ?
NB69	M4nX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnxfHFKSzVyPUG2NU45KG6P	MVzTRW5ITVJ?
EoL-1	NHWxSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTF6Nz6yOkBvVQ>?	MmDCV2FPT0WU
BHT-101	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\peXNKSzVyPUG5PE4zPSCwTR?=	M1TieHNCVkeHUh?=
SK-NEP-1	MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fSV2lEPTB;MkKwMlAzKG6P	M1K5NXNCVkeHUh?=
MHH-NB-11	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTJ{MD6xPUBvVQ>?	NIjOZlJUSU6JRWK=
AsPC-1	NX3EfYhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTJ3Mj61N{BvVQ>?	MorqV2FPT0WU
ES1	NUHMSGRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlP3TWM2OD1{NU[uNlUhdk1?	NFfZU2lUSU6JRWK=
LAMA-84	NGjielNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnKXmM1UUN3ME2yOVgvOTlibl2=	MnLmV2FPT0WU
MOLT-16	M2LJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEL3Vo9KSzVyPUK1PE41QSCwTR?=	MU\TRW5ITVJ?
ES7	M4HKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIqyWmFKSzVyPUK3N{4xQSCwTR?=	NXvmPHhIW0GQR1XS
KY821	NWTjUFJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTNzND6xJI5O	MUXTRW5ITVJ?
RT-112	NEG0OlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTN{MT6wOUBvVQ>?	MkHFV2FPT0WU
HL-60	NVXGWG1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\2dVJKSzVyPUO0NE43PiCwTR?=	MWnTRW5ITVJ?
MOLT-4	M17FUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTN2NT6xN{BvVQ>?	NHTucY5USU6JRWK=
KARPAS-45	M1nTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLsTWM2OD1\|N{[uNVYhdk1?	MoOyV2FPT0WU
SK-N-AS	NXLHbFB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3KyTmlEPTB;M{i3Mlg{KG6P	NFO2SWRUSU6JRWK=
CTB-1	MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXWTWM2OD12MEWuNFIhdk1?	M2myWXNCVkeHUh?=
NKM-1	Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTRzMT64PUBvVQ>?	NF\hZo5USU6JRWK=
HTC-C3	NGD3b2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTR\|Mj65OUBvVQ>?	MW\TRW5ITVJ?
BE-13	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrVTWM2OD12NESuNlchdk1?	Mn;NV2FPT0WU
KOSC-2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTR4Nj65JI5O	MV;TRW5ITVJ?
NB14	NELVclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\zTWM2OD12OEOuOVghdk1?	NWXLe3NKW0GQR1XS
CAL-27	M{S5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTR7ND61PUBvVQ>?	MXPTRW5ITVJ?
H9	NYfrOIc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33nd2lEPTB;NEm1MlQ{KG6P	Mm\YV2FPT0WU
RS4-11	NEfqcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vlN2lEPTB;NUC0Mlc{KG6P	NWPTPWE2W0GQR1XS
PA-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEX4TndKSzVyPUWwPU45PiCwTR?=	MYLTRW5ITVJ?
MV-4-11	NV:1R2hCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTVzMz64OUBvVQ>?	MXPTRW5ITVJ?
OS-RC-2	Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHycGtKSzVyPUWyNU43OiCwTR?=	NGnxcW1USU6JRWK=
RPMI-8226	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILqWGRKSzVyPUWyOk45PiCwTR?=	M1;JT3NCVkeHUh?=
HGC-27	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nOdmlEPTB;NU[0Mlk6KG6P	MojoV2FPT0WU
CHP-212	NF;iVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTV7Mz61PUBvVQ>?	NWfL[o5IW0GQR1XS
NB10	NHrIUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnH3TWM2OD13OUmuNVghdk1?	NVjwWJJUW0GQR1XS
HH	MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL3W3g6UUN3ME21PVkvPDNibl2=	NGTWZZBUSU6JRWK=
EW-16	NWqxdmg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoX3TWM2OD14MEOuOVIhdk1?	MX7TRW5ITVJ?
ES8	NVHn[FVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn1R2F5UUN3ME22NFUvOjFibl2=	MXTTRW5ITVJ?
HAL-01	NV;jUGVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjDXoJKSzVyPU[wOU43PyCwTR?=	NXr4PHh4W0GQR1XS
A204	NXPZUnl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXDflVJUUN3ME22N\|MvQTFibl2=	MVXTRW5ITVJ?
MHH-PREB-1	M{O5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPTeI9KSzVyPU[zOk46QSCwTR?=	NInzeoJUSU6JRWK=
EM-2	M{XybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFK3NHdKSzVyPU[1NE43PCCwTR?=	NXP3SYRUW0GQR1XS
BV-173	MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTZ3Mj60PEBvVQ>?	NFXRfHhUSU6JRWK=
ONS-76	NHL6[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTZ5Nz64NkBvVQ>?	MUnTRW5ITVJ?
KM-H2	MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PQS2lEPTB;Nkm1MlU1KG6P	MoC4V2FPT0WU
D-263MG	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHf2V3lKSzVyPUexO{4yOiCwTR?=	MX;TRW5ITVJ?
ES3	M3XNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHRTWM2OD15MkiuPVMhdk1?	MnLiV2FPT0WU
VA-ES-BJ	NIX5WG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2D2[mlEPTB;N{OyMlI4KG6P	M4\3V3NCVkeHUh?=
NBsusSR	NV3yclVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHz3[\|hKSzVyPUe0Nk46QSCwTR?=	NVfoO21lW0GQR1XS
NCI-H520	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33VeWlEPTB;N{S2MlUzKG6P	Mn;ZV2FPT0WU
ES5	NHrIPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLyTWM2OD15NUKuPEBvVQ>?	MWjTRW5ITVJ?
T-24	M2\sRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPqcllKSzVyPUe3PE44OSCwTR?=	NXPnZpEzW0GQR1XS
SW962	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrkTWM2OD16MEiuOlMhdk1?	NFrOcmVUSU6JRWK=
EW-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XCOGlEPTB;OEC4Mlc3KG6P	M3vXZXNCVkeHUh?=
RXF393	NFriTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjLSJF{UUN3ME24NVIvPzlibl2=	NX\ROXBnW0GQR1XS
U251	MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRThzMz64PEBvVQ>?	M{TmR3NCVkeHUh?=
CAMA-1	NYrZbmdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\MTWM2OD16M{OuPVQhdk1?	MWDTRW5ITVJ?
JVM-3	NUTucGhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3q4OWlEPTB;OEWxMlc5KG6P	Mnf2V2FPT0WU
COLO-800	NE[2PWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDzTWM2OD16OUeuO\|ghdk1?	MlzwV2FPT0WU
OVCAR-5	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWT3W4htUUN3ME25NFAvOSCwTR?=	M1PxXHNCVkeHUh?=
LB1047-RCC	NHrBNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTl{Nz61OkBvVQ>?	NV\VT5Q3W0GQR1XS
SW954	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTl{OT60NUBvVQ>?	MXXTRW5ITVJ?
J-RT3-T3-5	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTl\|Nj6wOkBvVQ>?	NX\jSFhsW0GQR1XS
Mewo	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XOfmlEPTB;OUO2MlYhdk1?	NVzEcpRKW0GQR1XS
NCI-H1770	NH75b25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTl2MD61OUBvVQ>?	NWe1bId6W0GQR1XS
HO-1-N-1	NIS5dJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojITWM2OD17NkKuPFEhdk1?	M3\RcnNCVkeHUh?=
HSC-3	NW\FfpVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTl4Nj60PEBvVQ>?	MV\TRW5ITVJ?
TYK-nu	M3m0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfZTWM2OD17OUiuNlUhdk1?	NVHn[nNMW0GQR1XS
KYSE-150	NVXF[WRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3f4S2lEPTB;MT6wNFA4PiEQvF2=	NXHCXW5UW0GQR1XS
SN12C	NF\n[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTlTWM2OD1zLkCwPFc2KM7:TR?=	MVPTRW5ITVJ?
MOLT-13	NEjKS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXqPWw6UUN3ME2xMlAyPDJzIN88US=>	NHvkeVJUSU6JRWK=
TE-11	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnuSXpKSzVyPUGuNFQ5OTJizszN	NEXN[nBUSU6JRWK=
DB	NHeyXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGThWXZKSzVyPUGuNFczPzNizszN	M4PEdXNCVkeHUh?=
CAL-39	NFrLV\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTFwMEe1NlIh\|ryP	M33pZXNCVkeHUh?=
A3-KAW	NHn5[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPFS3VkUUN3ME2xMlA5PDB6IN88US=>	MmDmV2FPT0WU
CHP-134	M4fU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33JRWlEPTB;MT6xNVgxPyEQvF2=	Mo\sV2FPT0WU
TGW	MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIW1WnpKSzVyPUGuNVI{QTVizszN	NFjKb4JUSU6JRWK=
QIMR-WIL	M4HPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPuTWM2OD1zLkGzNVM1KM7:TR?=	MXLTRW5ITVJ?
NCI-SNU-1	M3\6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LrdWlEPTB;MT6xOlM2PCEQvF2=	NGPodHBUSU6JRWK=
CGTH-W-1	M{n4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFeyNo9KSzVyPUGuNVcyQDZizszN	NEf6XIpUSU6JRWK=
MHH-ES-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTGdodKSzVyPUGuNVc6QDZizszN	Mn3uV2FPT0WU
LB2241-RCC	NYXMT4FoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvIbYxKSzVyPUGuNVg3OiEQvF2=	NUX6R41nW0GQR1XS
ML-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXjTWM2OD1zLkKwO\|M1KM7:TR?=	MVzTRW5ITVJ?
COR-L23	MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmn1TWM2OD1zLkKyPVM{KM7:TR?=	MnPHV2FPT0WU
BFTC-905	M1mwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P2V2lEPTB;MT6yOFI3PyEQvF2=	NVfwVYNiW0GQR1XS
Hs-578-T	Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zwWmlEPTB;MT6yOVgyPyEQvF2=	NFfIeJhUSU6JRWK=
KG-1	M2raV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTFwMk[2PFYh\|ryP	NE\jXVhUSU6JRWK=
HEL	M{SyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;MeJpbUUN3ME2xMlI6OzN6IN88US=>	MVjTRW5ITVJ?
A549	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFO0fVFKSzVyPUGuNlk{QTlizszN	NFnaTXJUSU6JRWK=
COLO-741	NF32eY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTFwM{KwPFkh\|ryP	MmrZV2FPT0WU
PC-3	M{m5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmn3TWM2OD1zLkO1NlIyKM7:TR?=	Ml30V2FPT0WU
HOS	Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojMTWM2OD1zLkO1Nlk3KM7:TR?=	NITHUVJUSU6JRWK=
HT-1080	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFwM{e1NVkh\|ryP	MYfTRW5ITVJ?
TE-8	M1u0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nDSGlEPTB;MT60NVc4PCEQvF2=	NH62eWZUSU6JRWK=
BHY	M4rVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTFwNE[5NlMh\|ryP	MVvTRW5ITVJ?
BB65-RCC	MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PrVGlEPTB;MT61NFUzQCEQvF2=	NHTTWGJUSU6JRWK=
HN	M{n4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfpPYFKSzVyPUGuOVQxPzFizszN	NXHRT\|ZlW0GQR1XS
NCI-H441	NFez[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWi5TJNnUUN3ME2xMlU1QTB5IN88US=>	MmTJV2FPT0WU
RPMI-8866	M4nx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTFwNUi1NFch\|ryP	Mo\iV2FPT0WU
CAL-62	MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HpSWlEPTB;MT62NFg3OiEQvF2=	NHTROmhUSU6JRWK=
MG-63	MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHaTWM2OD1zLk[xPFE{KM7:TR?=	NInSVVlUSU6JRWK=
SK-LU-1	NYDYTI84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7NTWM2OD1zLk[yNVUzKM7:TR?=	NVHNOGJLW0GQR1XS
BCPAP	NHrIN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLFTWM2OD1zLk[2OFU4KM7:TR?=	MV;TRW5ITVJ?
22RV1	M3TPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULLfoVCUUN3ME2xMlY4QDR\|IN88US=>	MW\TRW5ITVJ?
T47D	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnKxTWM2OD1zLk[4NFYyKM7:TR?=	MoLpV2FPT0WU
MSTO-211H	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXkZpNKSzVyPUGuOlk3ODNizszN	M2LwdnNCVkeHUh?=
DEL	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVOwXIR4UUN3ME2xMlcxOjd\|IN88US=>	MXPTRW5ITVJ?
H4	NFLyO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTFwN{OyNVIh\|ryP	Ml;yV2FPT0WU
CAL-51	MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTFwN{S4OVUh\|ryP	NIDtcIVUSU6JRWK=
ABC-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rxOWlEPTB;MT63PFU5OiEQvF2=	NXv1Z3dpW0GQR1XS
MZ2-MEL	NX\5bpVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTFwN{m1OFIh\|ryP	NViyfJliW0GQR1XS
YKG-1	M1rtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlThTWM2OD1zLkixNFYyKM7:TR?=	Ml7xV2FPT0WU
KM12	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjPT4NpUUN3ME2xMlgyPjB{IN88US=>	M3jsOXNCVkeHUh?=
L-363	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTFwOEe0NVIh\|ryP	M1\NNXNCVkeHUh?=
KU812	NUS3WIZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nTe2lEPTB;MT64PVI5OiEQvF2=	NWrYXHh4W0GQR1XS
LOXIMVI	NX\xXpVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1qz[mlEPTB;MT65NVIzQCEQvF2=	NFnyTFJUSU6JRWK=
G-401	M3;Jfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjBTWM2OD1zLkmyOFI5KM7:TR?=	MkXOV2FPT0WU
SW780	NUjRN2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTSTWM2OD1zLkm2NlQ3KM7:TR?=	NUDQfFZ2W0GQR1XS
SW872	NYXDeppET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUW5Vpc5UUN3ME2xMlk5OzNizszN	M1TZPHNCVkeHUh?=
NB7	NIDKT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTFwOUmzNlMh\|ryP	NF\nXYJUSU6JRWK=
T98G	MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;wWFZKSzVyPUKuNFA3PjZizszN	MmW3V2FPT0WU
SW1710	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEju[pVKSzVyPUKuNFY6PDVizszN	M4L3b3NCVkeHUh?=
NCI-H1573	NXj0c5B[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfFWnNKSzVyPUKuNFczQThizszN	MWLTRW5ITVJ?
KE-37	NUH5S2NQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmGxTWM2OD1{LkC4PVUyKM7:TR?=	MkjaV2FPT0WU
786-0	M3\XSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEi1dGdKSzVyPUKuNVU1OzlizszN	NV7wZo9{W0GQR1XS
SAS	M2LUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe0eW1KSzVyPUKuNlA{PzRizszN	MWPTRW5ITVJ?
CAL-54	NHvVOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HXfmlEPTB;Mj6yNFQyOyEQvF2=	M1nMb3NCVkeHUh?=
SF268	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvLcJlKSzVyPUKuNlMyOjJizszN	NHraXJdUSU6JRWK=
SW620	Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPSTWM2OD1{LkK2NVY6KM7:TR?=	NXnXRmVVW0GQR1XS
MN-60	NU\sNW9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LXOWlEPTB;Mj6zNVA3KM7:TR?=	NF\MPJVUSU6JRWK=
EFO-27	M3XLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFn1V\|hKSzVyPUKuN\|IxPThizszN	MmHBV2FPT0WU
NCI-H747	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYexZlMyUUN3ME2yMlMzOTl7IN88US=>	NF7hTFhUSU6JRWK=
HCC2218	NYXKOmE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPNcIFuUUN3ME2yMlM2Ozd2IN88US=>	MWHTRW5ITVJ?
MIA-PaCa-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDCNnZyUUN3ME2yMlM3PDN5IN88US=>	MUXTRW5ITVJ?
SJSA-1	NUTFeGc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HrUGlEPTB;Mj6zO\|c6PiEQvF2=	M1faPXNCVkeHUh?=
RKO	M4LJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M334TWlEPTB;Mj6zPFQ6PiEQvF2=	NYjnRpV3W0GQR1XS
NB6	M{TYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTJXZNKSzVyPUKuOFA{PzRizszN	M4jEZnNCVkeHUh?=
ES4	NW[2eWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moe3TWM2OD1{LkS1OFIzKM7:TR?=	MkTNV2FPT0WU
EGI-1	MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkj1TWM2OD1{LkS2PFg{KM7:TR?=	NYDTVIM6W0GQR1XS
CTV-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYr3WWQzUUN3ME2yMlUzPzd\|IN88US=>	M3rJO3NCVkeHUh?=
NCI-H1355	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYruTIVJUUN3ME2yMlU2QTVzIN88US=>	M{e4UHNCVkeHUh?=
GT3TKB	NFvkRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHhTWM2OD1{LkW5NVk6KM7:TR?=	M3XwWXNCVkeHUh?=
SK-HEP-1	MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjhdXFKSzVyPUKuOVkzPjZizszN	NGnad2NUSU6JRWK=
GAMG	NXznSFFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTJwNUmzPVQh\|ryP	MmLPV2FPT0WU
SK-MES-1	M13oRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTJwNkG4NFMh\|ryP	NHzsTZNUSU6JRWK=
RO82-W-1	M3LrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTJwNkKwOVch\|ryP	NUL5fohYW0GQR1XS
ECC10	M1HLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzsSlRKSzVyPUKuO\|AzODZizszN	NIK5S25USU6JRWK=
MCF7	M3XnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vheWlEPTB;Mj63NVQ3PCEQvF2=	Mn\NV2FPT0WU
D-283MED	NXLKT4NUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfPTWM2OD1{LkeyOFMh\|ryP	NHfMfJlUSU6JRWK=
RPMI-7951	MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TYcGlEPTB;Mj63OVY6PCEQvF2=	MYDTRW5ITVJ?
Ramos-2G6-4C10	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLTTWM2OD1{Lke3NFk6KM7:TR?=	NFLuU5BUSU6JRWK=
KGN	Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfPcnNVUUN3ME2yMlgyQDh2IN88US=>	NX;SeGtGW0GQR1XS
NUGC-3	M3X2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nXZmlEPTB;Mj64NlUxPSEQvF2=	MlmyV2FPT0WU
NCI-H292	NVLac3d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojYTWM2OD1{Lki1NFU{KM7:TR?=	MkDWV2FPT0WU
Becker	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTJwOUW4N\|Ih\|ryP	MVrTRW5ITVJ?
NCI-H1299	M1jp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3RTWM2OD1\|LkC1NlY{KM7:TR?=	MkLVV2FPT0WU
ETK-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFz1OWlKSzVyPUOuNFU1OyEQvF2=	M2ntT3NCVkeHUh?=
TK10	Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fkbGlEPTB;Mz6yNFE3PSEQvF2=	NUXzVIk1W0GQR1XS
VMRC-RCZ	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDzTWM2OD1\|LkO2OFg5KM7:TR?=	NHnGNGNUSU6JRWK=
YH-13	NWfuTHU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{ezdGlEPTB;Mz60OFA4QSEQvF2=	NE\yUZlUSU6JRWK=
DU-145	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHCTnNKSzVyPUOuOFYzPjlizszN	MnrWV2FPT0WU
SW1088	NF\rTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmH6TWM2OD1\|LkS3OFch\|ryP	NHy0fohUSU6JRWK=
HOP-92	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF:3PVZKSzVyPUOuOVA{PDJizszN	MXLTRW5ITVJ?
KP-N-YS	NYLiTYZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;FVGlEPTB;Mz62NlE{QSEQvF2=	MoLiV2FPT0WU
NCI-H460	NFrRZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTNwNk[3N{DPxE1?	M{XRb3NCVkeHUh?=
U-2-OS	NFr1bo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3q4SmlEPTB;Mz63NlU{PSEQvF2=	NITuZYRUSU6JRWK=
A101D	MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nJXGlEPTB;Mz63Olk{PiEQvF2=	MXfTRW5ITVJ?
MDA-MB-231	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk[0TWM2OD1\|LkixPVUyKM7:TR?=	MknwV2FPT0WU
IST-MES1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPqTWM2OD1\|LkizNkDPxE1?	NFy5U29USU6JRWK=
COR-L105	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PKXWlEPTB;ND6wNVgh\|ryP	NWrQR3pRW0GQR1XS
NCI-H1437	Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTRwMEKzNFIh\|ryP	Mo\qV2FPT0WU
CAL-85-1	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;RWWZ3UUN3ME20MlAzPDZzIN88US=>	M2rsNXNCVkeHUh?=
MZ1-PC	NYH5W2tYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjIe4dKSzVyPUSuNVg2PTZizszN	MVHTRW5ITVJ?
VM-CUB-1	NFjnWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfNTWM2OD12LkOxNlg1KM7:TR?=	MYjTRW5ITVJ?
CHL-1	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGW2Xm5KSzVyPUSuN\|IyPjlizszN	NEi3S4xUSU6JRWK=
MDA-MB-361	M2LiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTRwM{OxOVMh\|ryP	NVX3VWoyW0GQR1XS
NCI-H661	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjmZYN5UUN3ME20MlUxODl{IN88US=>	MVjTRW5ITVJ?
EW-11	NF;oWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTRwNUKyN\|Eh\|ryP	MlLUV2FPT0WU
BEN	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXGTWM2OD12LkWyPFE2KM7:TR?=	NUjVT4ljW0GQR1XS
BFTC-909	MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XoNmlEPTB;ND61OlI4PSEQvF2=	MmjuV2FPT0WU
NCI-H2087	M{nEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXThVlkzUUN3ME20MlU5OTZ2IN88US=>	MWrTRW5ITVJ?
RVH-421	NXPFOoo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jwSmlEPTB;ND62OlY6KM7:TR?=	M3S5dXNCVkeHUh?=
P30-OHK	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTRwNkiwNFgh\|ryP	NYDRUJdkW0GQR1XS
NCI-H28	NEe2TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTRwOEG2OlEh\|ryP	NXv1fYNIW0GQR1XS
ES6	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3X5VGlEPTB;ND64N\|AyPiEQvF2=	MoS3V2FPT0WU
769-P	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTPTWM2OD12Lki1PVI3KM7:TR?=	NGjDSXJUSU6JRWK=
OE33	NYPrWpg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\tWVBHUUN3ME20Mlg5OTZzIN88US=>	NYe2N2NTW0GQR1XS
SW982	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHvV4RKSzVyPUSuPVUxPjFizszN	M{\pfXNCVkeHUh?=
A388	NXTaU2I5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP1TWM2OD13LkCyPVg{KM7:TR?=	MkmyV2FPT0WU
TI-73	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjY[4ZVUUN3ME21MlA3OTl2IN88US=>	MoX5V2FPT0WU
HCT-116	NIXMelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTVwMEm4PFkh\|ryP	M2KyfHNCVkeHUh?=
HuP-T3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fON2lEPTB;NT6xPFcxQSEQvF2=	NHH6XI5USU6JRWK=
G-402	NVLMZVRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTVwMUm0NVYh\|ryP	MWPTRW5ITVJ?
NCI-H1792	M2fFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jPeWlEPTB;NT6yOFYzOiEQvF2=	MYTTRW5ITVJ?
NCI-H209	M3f4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTVwMkW5OFIh\|ryP	NEnHOGNUSU6JRWK=
NCI-H1650	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTVwM{C2N\|Qh\|ryP	MmGzV2FPT0WU
LCLC-97TM1	NFG0bW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTVwM{G4NFgh\|ryP	NHPnN\|hUSU6JRWK=
S-117	NVjhdJFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDSO4x7UUN3ME21MlM3QTd4IN88US=>	M2GxUHNCVkeHUh?=
GI-ME-N	NHjRWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17oUmlEPTB;NT6zPVY5OSEQvF2=	NFLwclFUSU6JRWK=
NCI-H2122	M2LZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTVwNEmzPVch\|ryP	M2rrVXNCVkeHUh?=
NCI-H1793	M{PNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTVwNke1PVMh\|ryP	MWfTRW5ITVJ?
C2BBe1	NYPZ[pp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfoZXhKSzVyPUWuO\|AxQDhizszN	NVuzfJlJW0GQR1XS
TE-12	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPGTWM2OD13LkiwOVU3KM7:TR?=	M1[5enNCVkeHUh?=
LCLC-103H	M3ns[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\ZdYJKSzVyPUWuPVE4KM7:TR?=	NFXOVHlUSU6JRWK=
A673	NVTFb4V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfyUm5KSzVyPUWuPVE6OzJizszN	MUjTRW5ITVJ?
BB30-HNC	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlL1TWM2OD13Lkm4N\|Yh\|ryP	NUn3boRYW0GQR1XS
SF295	MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\iO4ZKSzVyPU[uNFA1OjJizszN	M1q2UXNCVkeHUh?=
KU-19-19	NFLZSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mli2TWM2OD14LkCxO\|MyKM7:TR?=	MnfZV2FPT0WU
CFPAC-1	M2XBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTZwMES0OFMh\|ryP	NEHMOmdUSU6JRWK=
LoVo	MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXUcXJmUUN3ME22MlA2ODZ\|IN88US=>	M{PqZXNCVkeHUh?=
8505C	NXy3ZWNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\HXYRKSzVyPU[uNFc2PzNizszN	NGrXWmlUSU6JRWK=
GMS-10	NU\5U5RpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVflS\|M4UUN3ME22MlE2ODB{IN88US=>	NFntfWZUSU6JRWK=
Ca9-22	NIGyblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTZwMU[3NUDPxE1?	MXzTRW5ITVJ?
DOK	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvtWlBKSzVyPU[uNlIxPzJizszN	MXHTRW5ITVJ?
FADU	NWTlSlNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjjXnViUUN3ME22MlI3ODN7IN88US=>	NX;oZ\|ZQW0GQR1XS
BxPC-3	M1y4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHS0fnNKSzVyPU[uNlc{OiEQvF2=	NUjTTYRzW0GQR1XS
CAL-33	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1OxZ2lEPTB;Nj6yPVIxOSEQvF2=	MXHTRW5ITVJ?
SHP-77	M1;XWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\4TWM2OD14LkOxOVEzKM7:TR?=	MlW1V2FPT0WU
LXF-289	NYrwVWtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXXXJNKSzVyPU[uN\|M1PTVizszN	NH;iPW1USU6JRWK=
GB-1	NF7HZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnkZ3pKSzVyPU[uN\|gzKM7:TR?=	Mn3VV2FPT0WU
KS-1	NVL3dVYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEGzWJNKSzVyPU[uN\|g1PDdizszN	NV\reFZSW0GQR1XS
D-502MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1G1TWlEPTB;Nj60NlM4PiEQvF2=	NVLkSpozW0GQR1XS
LAN-6	MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTZwNUGwNlMh\|ryP	MmTPV2FPT0WU
H-EMC-SS	M{jETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTZwNU[xOFch\|ryP	M3fVbnNCVkeHUh?=
LC-2-ad	NFPseWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTZwNkCwO\|Yh\|ryP	MYXTRW5ITVJ?
NCI-H1693	NXS2NYY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTZwNkKyNVUh\|ryP	MknwV2FPT0WU
SK-N-FI	NVTQcpJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvoco1IUUN3ME22Mlc2ODR2IN88US=>	NHfKR4pUSU6JRWK=
D-423MG	NFvWSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETvcZpKSzVyPU[uO\|YyOTdizszN	MnHoV2FPT0WU
KNS-42	NYLpNlBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF6xR4xKSzVyPU[uO\|gyQTdizszN	NF\3dnVUSU6JRWK=
GCT	NY\6Tm5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XifGlEPTB;Nj65N\|gh\|ryP	MmW3V2FPT0WU
DSH1	NVPnVVI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\QTWM2OD15LkC2N\|Mh\|ryP	MnX3V2FPT0WU
D-247MG	M3LRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nBN2lEPTB;Nz6wO\|g5OSEQvF2=	NVG5d3FLW0GQR1XS
NCI-SNU-5	M1vZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TNSWlEPTB;Nz6xPFM4OSEQvF2=	NVj0RYxPW0GQR1XS
TE-6	NWGwVoljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTdwMkC2NFEh\|ryP	NXzkcmJOW0GQR1XS
NOMO-1	NH7KZ\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPZflVKSzVyPUeuNlIyOjdizszN	MkewV2FPT0WU
NB17	NVX0PJBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV36V3Y4UUN3ME23MlMxOzB7IN88US=>	NWfObodzW0GQR1XS
EW-22	NY\3R4ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEGxd5FKSzVyPUeuN\|Q{PDhizszN	MmHlV2FPT0WU
EW-13	MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTdwM{WxOlIh\|ryP	NE\pW5pUSU6JRWK=
DOHH-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nkRmlEPTB;Nz60OFAzKM7:TR?=	MWfTRW5ITVJ?
TGBC1TKB	M1OzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLOTWM2OD15LkS5PFk6KM7:TR?=	M3PLV3NCVkeHUh?=
GR-ST	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTdwNUK1PVQh\|ryP	NH25XpdUSU6JRWK=
KYSE-520	MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTdwNUW1NVUh\|ryP	Ml7QV2FPT0WU
CAPAN-1	NUPNcWVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoG0TWM2OD15LkW5OVEh\|ryP	NGm4XJhUSU6JRWK=
HCE-4	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTGOJhJUUN3ME23MlYzOjd7IN88US=>	NHfvfVNUSU6JRWK=
MLMA	NXLUe4ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTdwNkK5OVch\|ryP	MUPTRW5ITVJ?
HT-144	NY\0bJY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzi[45KSzVyPUeuOlU{PjhizszN	NVfLPJNlW0GQR1XS
KYSE-180	NWXxN45mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3O1SmlEPTB;Nz63NVE3QSEQvF2=	M3HhfXNCVkeHUh?=
TE-5	NVHIOGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fDd2lEPTB;Nz65OVk4OSEQvF2=	Moq5V2FPT0WU
IGROV-1	NVuwU\|F6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzyPXNrUUN3ME23Mlk5PTVzIN88US=>	NYnsNYNiW0GQR1XS
NCI-H1581	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LDeWlEPTB;OD6wNVIh\|ryP	MYXTRW5ITVJ?
SW1990	NYO4TFFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXFTWM2OD16LkC0OlU6KM7:TR?=	NVjidok1W0GQR1XS
EFM-19	M3noWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jiNWlEPTB;OD6wPFU1PSEQvF2=	NYP2PZBPW0GQR1XS
OGR-1	M2HiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPwZ4JrUUN3ME24MlQ{ODJ\|IN88US=>	M2r1XnNCVkeHUh?=
U-118-MG	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRThwNEO0OlMh\|ryP	MXjTRW5ITVJ?
SK-OV-3	M3HMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYryXo5WUUN3ME24MlQ3PzZ3IN88US=>	NVXVVYFRW0GQR1XS
KNS-62	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoK4TWM2OD16LkWxO\|YyKM7:TR?=	NWO2ZXNwW0GQR1XS
GOTO	MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRThwNUe2N\|Uh\|ryP	Mor1V2FPT0WU
8305C	M1zrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrGSlNiUUN3ME24MlcxPDh2IN88US=>	M{PpZ3NCVkeHUh?=
RPMI-2650	NYTnUVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDRNHpKSzVyPUiuO\|E6PTVizszN	MVHTRW5ITVJ?
NEC8	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4i5c2lEPTB;OD63OFMxPyEQvF2=	NYPnOGNMW0GQR1XS
KYSE-450	NULwW5RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLzU3JCUUN3ME24Mlg3PTR6IN88US=>	MWLTRW5ITVJ?
RMG-I	NFvVboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PXbmlEPTB;OT6xOFA2QCEQvF2=	NH7JcodUSU6JRWK=
CAKI-1	NHfpSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEC2fGxKSzVyPUmuN\|E6PzlizszN	NWH4c\|FCW0GQR1XS
KYSE-510	M2SxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPXclJ{UUN3ME25MlM2Pzd6IN88US=>	NYrQUm9XW0GQR1XS
A4-Fuk	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHr4dWNKSzVyPUmuN\|Y4ODFizszN	M{LET3NCVkeHUh?=
AN3-CA	MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDYb41EUUN3ME25MlQ2PDR2IN88US=>	M2n6R3NCVkeHUh?=
SK-N-DZ	NYHiOnd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;MTWM2OD17LkeyPFQ6KM7:TR?=	NGjocmxUSU6JRWK=
HSC-2	NH25bItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWiwOpFDUUN3ME25Mlc3PjJ7IN88US=>	MULTRW5ITVJ?
EW-1	M1T4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTlwN{mzOlkh\|ryP	NIn6WZZUSU6JRWK=
D-566MG	NFXOXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTlwOEO2OlQh\|ryP	MUHTRW5ITVJ?
COLO-792	MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3Ue24zUUN3ME25Mlk5PzR4IN88US=>	M2fXenNCVkeHUh?=
TE-10	Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTFyLkCzPVYh\|ryP	M3;zT3NCVkeHUh?=
NCI-H650	NYXSRmE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYToS\|JDUUN3ME2xNE41Ojh4IN88US=>	M1fmZnNCVkeHUh?=
U-266	M331PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrLTWM2OD1zMD60OVUh\|ryP	NUjKNY5sW0GQR1XS
Detroit562	MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUH2OJJNUUN3ME2xNU4xPTF3IN88US=>	NFzi[JlUSU6JRWK=
NH-12	M3vaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PaW2lEPTB;MUGuNVQ1PiEQvF2=	MUHTRW5ITVJ?
CO-314	M13CcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3EXYFKSzVyPUGxMlI5PDJizszN	M4\ubnNCVkeHUh?=
IST-MEL1	NGjxbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nnNWlEPTB;MUGuOVMzOyEQvF2=	NEjqVYZUSU6JRWK=
KNS-81-FD	NInMUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\xTWM2OD1zMT61OVI4KM7:TR?=	NYnLWIV1W0GQR1XS
SW1463	NWPa[m5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELMRWVKSzVyPUGxMlU6QDlizszN	M4fD[nNCVkeHUh?=
NCI-H23	M{j1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTFzLk[1OVIh\|ryP	MkC1V2FPT0WU
SK-MEL-2	NV3PZ2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTFzLkexPVch\|ryP	MWXTRW5ITVJ?
NB13	NXKzW2xGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPMPWFlUUN3ME2xNk4yPDl3IN88US=>	M1;lZXNCVkeHUh?=
Daoy	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{f1OmlEPTB;MUKuNlg2PiEQvF2=	M1rMZXNCVkeHUh?=
NCI-H1623	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXhTWM2OD1zMj6zPFAyKM7:TR?=	NEfYdG5USU6JRWK=
NMC-G1	MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnxXWUzUUN3ME2xNk44OTdizszN	MX\TRW5ITVJ?
DK-MG	M1LaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTF{Lkm0PFIh\|ryP	NFTmW49USU6JRWK=
TCCSUP	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTHTWM2OD1zMz6xNlg1KM7:TR?=	MlTqV2FPT0WU
SCC-15	NXzwVlBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTF\|LkK2OVEh\|ryP	M3;EeHNCVkeHUh?=
NOS-1	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fJNGlEPTB;MUOuNlg6OyEQvF2=	M1LaPXNCVkeHUh?=
RH-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDmc3pKSzVyPUGzMlMxOzdizszN	NYHUSYdCW0GQR1XS
SK-MEL-3	NWqxfZhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TuTWlEPTB;MUOuN\|czQCEQvF2=	NE\OcHlUSU6JRWK=
NB5	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfaOYc2UUN3ME2xN{41ODZ5IN88US=>	MoLFV2FPT0WU
SNU-387	NV3aZWtZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTF\|LkWwO\|Ih\|ryP	Mnv0V2FPT0WU
CAL-120	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nRfGlEPTB;MUOuOlcyQCEQvF2=	MWrTRW5ITVJ?
Mo-T	NIrIXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7uTWM2OD1zMz63NFch\|ryP	M4KwbnNCVkeHUh?=
LNCaP-Clone-FGC	NF;ROWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHu4[pBKSzVyPUGzMlc6QTJizszN	NWWwWGp{W0GQR1XS
CAN	MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLqOGh4UUN3ME2xOE4xOjh6IN88US=>	MnrBV2FPT0WU
SK-MEL-30	NYLn[\|NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTF2LkC2N{DPxE1?	MkC4V2FPT0WU
COLO-678	M3TOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7wNVdKSzVyPUG0MlA5OjJizszN	MUHTRW5ITVJ?
SCC-9	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzTTWw{UUN3ME2xOE4yODJzIN88US=>	NF\vU5FUSU6JRWK=
KINGS-1	MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTF2LkG0NFIh\|ryP	MlOyV2FPT0WU
SL-513	M1HzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HkZWlEPTB;MUSuNVg4KM7:TR?=	M4npVXNCVkeHUh?=
HLE	NYrGXVBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTF2LkO4OVIh\|ryP	M{jvcnNCVkeHUh?=
SW1573	M1PZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTF2LkS0N\|Uh\|ryP	NIj1VlJUSU6JRWK=
KYSE-140	NWHzOHVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHNeY5KSzVyPUG0MlY{OjdizszN	MnPDV2FPT0WU
SK-PN-DW	NELJfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTF2LkiwNFEh\|ryP	NVKwO\|NRW0GQR1XS
A253	Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXUPJZKSzVyPUG1MlA3OjVizszN	M1\nXXNCVkeHUh?=
CAL-12T	NV;He41IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrBenpIUUN3ME2xOU41PjZ{IN88US=>	NIe2b4xUSU6JRWK=
COLO-679	NUS5TolXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTF3Lke2PFMh\|ryP	MYHTRW5ITVJ?
UACC-257	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLoTWM2OD1zNj6xNlAyKM7:TR?=	NHS5cFBUSU6JRWK=
U-87-MG	NG\5OVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;1UnBKSzVyPUG2MlM2OjNizszN	Mn7qV2FPT0WU
HCC1806	NUHhPZQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGe0SmlKSzVyPUG2MlcxPzFizszN	NHzpOG9USU6JRWK=
NCI-H2170	NFq0fVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkG5TWM2OD1zNz6yOFQ5KM7:TR?=	MoHVV2FPT0WU
AGS	NX2zSJczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTrWGw{UUN3ME2xO{4{QDB6IN88US=>	M4\5U3NCVkeHUh?=
MEL-HO	MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTF5Lke1NFMh\|ryP	NV\CeY1vW0GQR1XS
SW48	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPzVmVKSzVyPUG3Mlc4OTZizszN	MnrxV2FPT0WU
HuP-T4	NFnkXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjhOopKSzVyPUG4MlAzODZizszN	NHLy[IxUSU6JRWK=
NCI-H720	MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nobGlEPTB;MUiuNVQxOiEQvF2=	M{TMfHNCVkeHUh?=
RCC10RGB	NEPM[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULzdodPUUN3ME2xPE4yPjl5IN88US=>	Mkj1V2FPT0WU
HD-MY-Z	M32weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{KxbWlEPTB;MUiuNlI2PCEQvF2=	MnHhV2FPT0WU
A427	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnpTWM2OD1zOD61NFk1KM7:TR?=	MX3TRW5ITVJ?
HCC2998	NFK2UlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTF6Lk[wOVEh\|ryP	MoDiV2FPT0WU
EPLC-272H	NXTUboNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjFNG1KSzVyPUG5MlA1OzRizszN	NHPlXZNUSU6JRWK=
C32	MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPDXnF4UUN3ME2xPU4xPDVizszN	NHr4[JFUSU6JRWK=
UMC-11	MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELKWJpKSzVyPUG5MlIyOjNizszN	NGD2V3RUSU6JRWK=
CaR-1	NWXLTXBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTF7Lk[4NFQh\|ryP	MYjTRW5ITVJ?
KYSE-410	NYfnTXZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmG1TWM2OD1zOT65NVM6KM7:TR?=	MXHTRW5ITVJ?
HuCCT1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDQT2V6UUN3ME2yNE43Ojl2IN88US=>	NF7pVFJUSU6JRWK=
LB996-RCC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3Xx[GlEPTB;MkCuO\|E3QCEQvF2=	MUHTRW5ITVJ?
KYSE-70	NYHKfmN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPBTWM2OD1{MD64NFU6KM7:TR?=	NIrsZpFUSU6JRWK=
CAL-72	NYfte25LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nleGlEPTB;MkCuPVE2KM7:TR?=	MXrTRW5ITVJ?
Capan-2	M{DJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\LTWM2OD1{MT6wOFE{KM7:TR?=	M1PyfXNCVkeHUh?=
PANC-08-13	NVL4Zo9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1izTGlEPTB;MkGuNlUyPSEQvF2=	MX;TRW5ITVJ?
SBC-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjPWVlKSzVyPUKxMlMxQDFizszN	M{O1VXNCVkeHUh?=
MFM-223	M2niO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzsTWM2OD1{MT6zN\|QzKM7:TR?=	MVfTRW5ITVJ?
BB49-HNC	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWL4dGZqUUN3ME2yNU42PzF4IN88US=>	NUP6d3ZyW0GQR1XS
SH-4	M1nqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTJzLk[2NVgh\|ryP	MW\TRW5ITVJ?
HuO9	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PncGlEPTB;MkGuPVgzPSEQvF2=	M4DHZXNCVkeHUh?=
AM-38	NYjSdGJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTJ{LkC0PFUh\|ryP	NEXGNHJUSU6JRWK=
A431	M1XZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7jTWM2OD1{Mz6yNVE6KM7:TR?=	NILWcYVUSU6JRWK=
YAPC	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7Ue25KSzVyPUKzMlI3PTFizszN	NYnEXJkxW0GQR1XS
LU-139	NHjkWItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHMPGFKSzVyPUKzMlQ5ODlizszN	NG\mSnpUSU6JRWK=
HEC-1	Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkP1TWM2OD1{Mz60PVM4KM7:TR?=	NWDZO\|ljW0GQR1XS
SCC-25	M3HPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTJ2LkOwNFYh\|ryP	NX\3cZh4W0GQR1XS
HT-29	MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLvTWM2OD1{ND6zPFI{KM7:TR?=	M37MSnNCVkeHUh?=
PC-14	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF36bXNKSzVyPUK0MlY2PzFizszN	M4nyR3NCVkeHUh?=
Calu-6	M4rVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTJ3LkWwO\|Eh\|ryP	NYLwXlV{W0GQR1XS
SJRH30	M37mW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJ3Lk[0PVYh\|ryP	NHWyb\|RUSU6JRWK=
ChaGo-K-1	M1S2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LUbGlEPTB;Mk[uNVYzQSEQvF2=	NIfNTW9USU6JRWK=
IA-LM	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTJ4LkO2OFUh\|ryP	MUXTRW5ITVJ?
GP5d	NEO0XFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTJ4LkS0PVEh\|ryP	M{fYTXNCVkeHUh?=
NCI-H2291	M{nZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTJ4Lk[1OFEh\|ryP	NFvleHJUSU6JRWK=
BALL-1	NIjGNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3X2eWlEPTB;Mk[uPVM6PyEQvF2=	MV\TRW5ITVJ?
HCC1954	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;zWGlTUUN3ME2yOk46QDB6IN88US=>	M1OxeHNCVkeHUh?=
NCI-H2452	NFyxelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTJ5LkSxOlMh\|ryP	NGTMS3hUSU6JRWK=
LU-99A	MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoH6TWM2OD1{Nz61OVgzKM7:TR?=	Ml;VV2FPT0WU
NTERA-S-cl-D1	M{e4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTGOVh6UUN3ME2yO{44Ojl7IN88US=>	Mli5V2FPT0WU
PANC-10-05	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLUfIJKSzVyPUK3Mlc4PzVizszN	M4[xU3NCVkeHUh?=
NCI-H2405	NXqxeZF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\DfVhpUUN3ME2yO{46Ozh5IN88US=>	M2rwSnNCVkeHUh?=
MDA-MB-415	MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTJ6LkSxN\|ch\|ryP	MWHTRW5ITVJ?
NCI-H2342	NXPmcWFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nBUWlEPTB;MkiuOVI5OSEQvF2=	MVzTRW5ITVJ?
TGBC24TKB	NUfwc3FHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkGwTWM2OD1{OD63NVE4KM7:TR?=	NUPUfWFqW0GQR1XS
LU-134-A	M335fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zVUmlEPTB;MkiuPVI3OSEQvF2=	NWPndZlnW0GQR1XS
SCC-4	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnNNodjUUN3ME2zNU4xPDl2IN88US=>	M3jZfXNCVkeHUh?=
Saos-2	NIDJc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTNzLkmzNFYh\|ryP	NXP4T5ZKW0GQR1XS
RERF-LC-MS	NHfSTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1mweWlEPTB;M{KuPFI{OSEQvF2=	MYDTRW5ITVJ?
M14	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDFTWM2OD1\|Mj65O\|Y1KM7:TR?=	MoK5V2FPT0WU
HPAF-II	NVz4VJo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3ZTWM2OD1\|Mz61NFEyKM7:TR?=	Mom3V2FPT0WU
NCI-H1755	M1yy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPwTWM2OD1\|ND6zN\|A2KM7:TR?=	M4q2[HNCVkeHUh?=
D-392MG	M2nkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTN3Lki2O\|Qh\|ryP	NVG3VlhSW0GQR1XS
A704	NH3rS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTN4LkC0Nlch\|ryP	NGPqVYpUSU6JRWK=
CP50-MEL-B	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGry[G5KSzVyPUO2MlE6OTFizszN	NEPqW5BUSU6JRWK=
EW-18	MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrNe4pKSzVyPUO2MlQ2OiEQvF2=	MnjHV2FPT0WU
WM-115	MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkewTWM2OD1\|Nj64NFk6KM7:TR?=	M1rKfXNCVkeHUh?=
LU-65	MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoKxTWM2OD1\|Nz6xOFE4KM7:TR?=	M2LkenNCVkeHUh?=
NCI-H1563	NH;6WGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;ISYVKSzVyPUO3MlI1QDRizszN	MVzTRW5ITVJ?
DBTRG-05MG	M4XteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV[1foR7UUN3ME2zPE4xPjlzIN88US=>	Mnq0V2FPT0WU
NCI-H630	M3i0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLSTWM2OD1\|OD60O\|E1KM7:TR?=	MWLTRW5ITVJ?
NCI-H1155	NVPVVGg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPQTWM2OD1\|OT6yOFIh\|ryP	MYHTRW5ITVJ?
OVACR-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILaUlFKSzVyPUO5MlkyQTVizszN	NXHNd\|I4W0GQR1XS
OAW-42	MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzvPWRKSzVyPUSwMlQzPThizszN	M2O3TXNCVkeHUh?=
JVM-2	M4f5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDXTWM2OD12MT6yOFE2KM7:TR?=	M2r5[XNCVkeHUh?=
C3A	M17mfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XmXmlEPTB;NEGuN\|Q1PyEQvF2=	NX7CXmZLW0GQR1XS
HT55	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2[5SmlEPTB;NEKuNlg1OSEQvF2=	NG[5bllUSU6JRWK=
OVCAR-4	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jPdmlEPTB;NEKuNlk4PCEQvF2=	MUDTRW5ITVJ?
MEG-01	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITOR4xKSzVyPUSyMlQ3OTZizszN	NX3QNJJ3W0GQR1XS
NCI-H82	MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPzXYYzUUN3ME20N{46QDl{IN88US=>	NH\ISWRUSU6JRWK=
JEG-3	MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTHTWM2OD12ND65OFch\|ryP	NYnBR2JLW0GQR1XS
BPH-1	MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LYcmlEPTB;NE[uN\|k6QCEQvF2=	NH;JblRUSU6JRWK=
MPP-89	NYn1PWVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7FTWM2OD12Nz6yPFk5KM7:TR?=	NEXZOZNUSU6JRWK=
ALL-PO	MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnDTWM2OD12Nz60NVg5KM7:TR?=	NFW3XoVUSU6JRWK=
HT	M4mzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY[5XG1oUUN3ME20O{41QTJizszN	NY\2[XJ1W0GQR1XS
NCI-H2347	NUDyNJVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rx[mlEPTB;NEiuNFcyPSEQvF2=	NIroUnhUSU6JRWK=
A2780	MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTR7LkSyNlgh\|ryP	NELRUVNUSU6JRWK=
KARPAS-299	NImxSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPiWJp[UUN3ME20PU42OTF7IN88US=>	MmrMV2FPT0WU
NCI-H1651	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXtZnJoUUN3ME20PU45QDJzIN88US=>	MYrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; PubMed: 30300583 Cancer Cell Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells. pRb(S807, 811) / CDK4 / CDK6 / PARP; PubMed: 28453226 Mol Oncol Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. LC3-I / LC3-II; PubMed: 28453226 Mol Oncol Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. pAMPKα(T172) / pULK1(S317); PubMed: 28453226 Mol Oncol Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. SMAD2 (pS255); PubMed: 30343527 Cancer Sci T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.	30300583 28453226 30343527
Growth inhibition assay	Cell viability; PubMed: 29670090 Cell Death Dis Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.	29670090
Immunofluorescence	SAHF/ATRX; PubMed: 26988987 Cancer Res DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. LC3B; PubMed: 28453226 Mol Oncol LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).	26988987 28453226
ELISA	PGE2; PubMed: 26540629 Oncotarget The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.	26540629

In vivo

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research: ^[1]	- Collapse Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 Concentrations: 0.01-1 μM Incubation Time: 24 hours Method: Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0) Dosages: 0-150 mg/kg Administration: Given by gavage (Only for Reference)

References

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

- Collapse

Solubility (25°C)

In vitro	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Molecular Weight	483.99
Formula	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03870919	Not yet recruiting	Drug: Palbociclib\|Other: locoregional treatment	Breast Cancer Stage IV\|Radiotherapy\|Surgery	UNICANCER\|Pfizer	October 15 2019	Not Applicable
NCT03900884	Not yet recruiting	Drug: Venetoclax\|Drug: Palbociclib\|Drug: Letrozole	Breast Neoplasm Female	Peter MacCallum Cancer Centre Australia	September 2019	Phase 1
NCT03844997	Recruiting	Drug: Palcociclib\|Drug: CPX-351	Acute Myeloid Leukemia\|AML	Aziz Nazha\|Case Comprehensive Cancer Center	May 31 2019	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl

Cited by 155 Publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl

Cited by 155 Publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)